Agilent Technologies (NYSE:A) Price Target Lowered to $160.00 at Wells Fargo & Company

Agilent Technologies (NYSE:A – Get Rating) had its target price trimmed by Wells Fargo & Company from $170.00 to $160.00 in a research report report published on Wednesday morning, The Fly reports. The brokerage currently has an overweight rating on the medical research company’s stock.

A number of other analysts have also recently weighed in on A. Citigroup decreased their price objective on Agilent Technologies from $150.00 to $130.00 and set a neutral rating for the company in a research report on Wednesday. Credit Suisse Group increased their target price on Agilent Technologies from $165.00 to $170.00 and gave the stock an outperform rating in a research note on Wednesday, March 1st. Barclays cut their target price on Agilent Technologies from $140.00 to $135.00 and set an equal weight rating for the company in a research note on Wednesday. StockNews.com assumed coverage on Agilent Technologies in a research note on Thursday, May 18th. They set a buy rating for the company. Finally, Robert W. Baird raised their price objective on Agilent Technologies from $170.00 to $174.00 and gave the company an outperform rating in a research note on Wednesday, March 1st. Three analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat, Agilent Technologies has an average rating of Moderate Buy and an average price target of $151.35.

Agilent Technologies Stock Down 5.9 %

Shares of NYSE A opened at $120.99 on Wednesday. The stock has a market cap of $35.78 billion, a PE ratio of 27.31, a price-to-earnings-growth ratio of 1.89 and a beta of 1.03. The company has a quick ratio of 1.53, a current ratio of 2.11 and a debt-to-equity ratio of 0.49. Agilent Technologies has a 52-week low of $112.52 and a 52-week high of $160.26. The business has a 50-day moving average price of $133.87 and a 200 day moving average price of $144.11.

Agilent Technologies (NYSE:A – Get Rating) last posted its quarterly earnings data on Tuesday, May 23rd. The medical research company reported $1.27 earnings per share for the quarter, topping analysts’ consensus estimates of $1.26 by $0.01. Agilent Technologies had a return on equity of 30.35% and a net margin of 19.09%. The company had revenue of $1.72 billion during the quarter, compared to analysts’ expectations of $1.67 billion. During the same period last year, the firm earned $1.13 EPS. The firm’s revenue for the quarter was up 6.8% on a year-over-year basis. Equities research analysts forecast that Agilent Technologies will post 5.68 earnings per share for the current year.

Agilent Technologies Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 26th. Stockholders of record on Monday, July 3rd will be issued a dividend of $0.225 per share. This represents a $0.90 annualized dividend and a dividend yield of 0.74%. The ex-dividend date is Friday, June 30th. Agilent Technologies’s dividend payout ratio (DPR) is 20.32%.

Institutional Investors Weigh In On Agilent Technologies

Several hedge funds have recently made changes to their positions in the business. BlackRock Inc. boosted its holdings in shares of Agilent Technologies by 1.9% during the third quarter. BlackRock Inc. now owns 32,943,190 shares of the medical research company’s stock worth $4,004,242,000 after purchasing an additional 629,153 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Agilent Technologies by 1.0% during the third quarter. Vanguard Group Inc. now owns 24,955,720 shares of the medical research company’s stock worth $3,033,368,000 after purchasing an additional 257,455 shares during the last quarter. State Street Corp boosted its holdings in shares of Agilent Technologies by 0.6% during the third quarter. State Street Corp now owns 13,152,295 shares of the medical research company’s stock worth $1,598,661,000 after purchasing an additional 73,495 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Agilent Technologies by 6.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 8,218,926 shares of the medical research company’s stock valued at $1,137,008,000 after acquiring an additional 511,874 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its holdings in Agilent Technologies by 10.7% in the third quarter. Massachusetts Financial Services Co. MA now owns 6,478,670 shares of the medical research company’s stock valued at $787,483,000 after acquiring an additional 627,517 shares during the last quarter.

Agilent Technologies Company Profile

(Get Rating)

Agilent Technologies, Inc engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level.